AI-Driven Precision Medicine Market Size, Share, Growth Opportunity Analysis Report by Technology Type (Machine Learning (ML), Deep Learning (DL), Natural Language Processing (NLP), Computer Vision, Reinforcement Learning, Big Data Analytics, Others), Component, Data Type, Delivery Mode, Therapeutic Area, Application, End-user and Geography (North America, Europe, Asia Pacific, Middle East, Africa, and South America) – Global Industry Data, Trends, and Forecasts, 2025–2035.
|
Market Structure & Evolution
|
- The global AI-driven driven precision medicine market is valued at USD 0.7 billion in 2025.
- The market is projected to grow at a CAGR of 26.8% during the forecast period of 2025 to 2035.
|
|
Segmental Data Insights
|
- The machine learning segment holds major share ~39% in the global AI-driven driven precision medicine market. Owing to its diagnosing and treating genetic illnesses and complex disorders like cancer, ML has particularly excelled.
|
|
Demand Trends
|
- Rising demand for early cancer detection using AI-based diagnostics – Example: Freenome is leveraging AI-driven multiomics to enhance early-stage cancer screening solutions.
- Personalized treatment optimization through AI-enabled genomics – Example: Tempus Labs uses AI to analyze genomic and clinical data to tailor cancer therapies for patients.
|
|
Competitive Landscape
|
- The global AI-driven driven precision medicine market is moderately fragmented, with the top five players accounting for over 64% of the market share in 2025.
|
|
Strategic Development
|
- In April 2025, Tempus AI Launches “Tempus One” Portable AI Device to Advance Cost-Effective Precision Oncology.
- In April 2025, PathAI Partners with Mayo Clinic to Deploy AI-Enabled Pathology Models for Real-Time Cancer Diagnosis.
|
|
Future Outlook & Opportunities
|
- Global AI-driven driven precision medicine market is likely to create the total forecasting opportunity of USD 9.0 Bn till 2035.
- North America is most attractive region.
|
AI-Driven Precision Medicine Market Size, Share, and Growth
The global market for AI-driven precision medicine is likely to grow at an extraordinary compound annual growth rate (CAGR) of 26.8% from USD 0.7 billion in 2025 to USD 9.7 billion by 2035. The aging population, growing prevalence of chronic conditions, and the need for faster, more accurate care has all fueled interest in AI-driven precision medicine. Increasingly, age-related conditions such as diabetes, heart disease, and cancer are rising.

In March 2024, healthcare leaders such as Tempus and PathAI continue to advance AI-driven precision medicine in parallel with the industry-wide goal for intelligent, individualized treatment. New artificial intelligence tools are being developed around cancer and genetic diseases that deliver better patient tracking, personalized treatments, and the ability for doctors to make quicker diagnoses. The emerging artificial technology assistance capabilities in the form of real-time decision support or enhanced data analytics, and the faster output results, will give doctors the ability to respond immediately and more accurately.
By using patient history, testing information, and genomic data, artificial intelligence systems assist clinicians in determining the best possible treatment paths to take and assisting clinicians in the ability to make wrenching, follow-up treatment decisions with a lower incidence of trial and error. Several AI-driven precision medicine tools, such as genomics analysis, predictive models, and image-based diagnosis have been increasingly used in recent years.
Furthermore, it providing targeted therapy with less trial-and-error, limited side effects while increasing efficiencies in health care particularly for difficult or drug-resistant diseases. For instance, with the help of Tempus's AI platform doctors to make quicker, more precise decisions before the illness complexes. Additionally, governments and global health firms with initiatives like World Cancer Day and awareness-raising tactics from the American Cancer Society and Global Genes are helping the cause. These trends are providing opportunities to improve healthcare, individualized success, speed, and accessibility overall.

AI-Driven Precision Medicine Market Dynamics and Trends
Market Drivers: Rising Incidence of Genetic Disorders with increasing Technological Advancements
- The rise in cases of tumors, rare genetic disorders and just the overall increase of chronic disease like diabetes and related heart disease represents the expansion of the AI-driven precision medicine landscape. According to the National Institutes of Health, precision medicine improves health outcomes by treating patients based on their genes, environment, and lifestyles. When patients do not respond to traditional treatments, AI-driven precision medicine offers a more targeted, data-driven, and longer-term plan.
- Advances in AI and its application into diagnostics with deep learning for diagnostic imaging interpretation, genomic data interpretation, monitoring of patients in real time, and digital twin for pharmacological models, have extended the influence and scope of precision medicine through AI innovation. This technology is ushering in remote changes, accelerating more precise judgments of physicians, and ultimately reducing hospital in patient visits.
Market Restraints: Expensive AI Models, Strict Regulatory Frameworks limiting the AI-Driven Precision Medicine Industry
- The AI-based precision medicine market, particularly in low-resource environments, has substantial limitations that lead to the inability for general application. Such as to create AI models, purchase data infrastructure, and hire capable talent, costs are high enough that smaller hospitals or clinics cannot use these tools. Advanced tools such as Tempus and IBM Watson require on-going support and update, as well as integration with health records and the secure transfer of confidential patient data, likewise requiring significant investment. Thus, areas without significant funding and digital are still beyond reach.
- Further adding rigid regulatory environments and limited access to health data are also delaying growth in AI precision medicine. With sufficient clinical data, safety and performance measures must follow stringent regulations established by bodies like the FDA or EMA. In contrast, lack of digital data sharing, fragmented health systems, and imprecise regulations surrounding healthcare data sharing present considerable challenges in many countries, consequently delaying their ability to improve diagnosis, individualize treatment, and mitigate inequities in healthcare around the world.
Opportunity: Predictive Analytic with Real-Time Decisions in Clinical Workflows
- With the growth of data science, predictive analytics and incorporation into clinical workflows, the market for data-driven precision medicine is rapidly expanding. Companies are increasingly using AI to analyze genetic information, lifestyle factors and medical history to design highly tailored treatment plans. This is particularly relevant and has broad potential in preventative medicine and chronic disease management, especially in cardiovascular and metabolic diseases, where tools like Owkin's AI models are helping researchers to identify new biomarkers and speeding the design of clinical trials.
- Microsoft and Roche made significant growth in this field in 2024. Microsoft's Azure AI is establishing real-time clinical decision support systems across large health systems, thus allowing for quicker and more accurate treatment for patients. Roche's NAVIFY platform is using artificial intelligence to improve oncology workflows to allow oncologists to be able to identify patients for the most appropriate treatments based on tumor profiling. The influence of artificial intelligence as a rapidly expanding driver of faster, widely accessible precision healthcare worldwide should not go unnoticed.
Key Trend: Shift toward Machine Learning
- The precision medicine industry is seeing a force for change in artificial intelligence (AI) tools based on machine learning (ML). For example, in oncology cancer treatment, AI/ML systems like Tempus and PathAI are providing physicians with more effective treatment recommendations by utilizing large amounts of genetic and clinical data. There are studies indicating that ML models can predict patient response to medicines with great accuracy, and provide better outcomes while minimizing trial-and-error approaches to therapeutics. The continued emergence of data, confirmed diagnostic outcomes, and easy adoption into the clinical workflow has made ML-based technologies the preferred support system for modern personalized treatment.
- Diagnosis has long relied on human interpretation of test results. Not anymore. Machine learning is changing this by delivering faster and more accurate results from an AI driven system that can learn from new data in real-time. Deep learning methods are aiding pathologists, for example, by reducing diagnostic error and increasing decision-making ability while helping to identify signs of cancer. These tools help to improve the quality of care as well as provide better diagnosis from learning from experience.
AI-Driven Precision Medicine Market Analysis and Segmental Data

Based on Technology Type, Machine learning based models are leading with the Largest Share
- The fast-growing AI-led precision medicine sector is increasingly influenced by machine learning (ML). When it comes to diagnosing and treating genetic illnesses and complex disorders like cancer, ML has particularly excelled. The capability of ML in decision-making is predictive when it draws from large data sets that include aspects of the patient history, genetic tests, and lab assessments of patients. It not only preserves unnecessary treatments, but helps to eliminate guess work. As hospitals strive for better outcomes while simultaneously cutting costs, they are turning to ML technologies as they become more reliable and readily accessible to the doctor.
- Moreover, the ML only algorithm is also able to rapidly analyze real-time patient data, updating recommendations as necessary. Longitudinal care is achievable with ML systems because they can track the course of a patient and update recommendations for them over time. The flexible and proven accuracy, speed and cost-effective nature of ML make it an attractive option for clinicians looking to provide intelligent, personalized and future health care.
North America Dominates AI-Driven Precision Medicine Market in 2025 and beyond
- The rapid surge in demand for AI-enabled precision medicine is largely due to its known benefits, including individualized therapies, reduced diagnostic time, and improved outcomes for disease such as cancer and inborn errors of metabolism, especially in North America. Patients and physicians appreciate artificial intelligence capabilities because they provide more precise, accurate answers with reduced trial-and-error than traditional pathways. By honing in on the appropriate therapies for each individual, this disruptive change is reducing long-term costs and enhancing overall patient care quality.
- The U.S. is leading AI based precision medicine research because of its abundant technical infrastructure, widespread health databases, and favorable government policy. Advanced care is becoming accessible through health insurance for AI technology used in testing and diagnosis and the FDA is also accelerating approvals of artificial intelligence technologies aided by new digital health standards. Therefore, North America leads the world in influencing the future direction of precision medicine by creating premier studies, fuelled by very robust funding, a virtuous innovation cycle.
AI-Driven Precision Medicine Market Ecosystem
Key players in the global AI-driven driven precision medicine market include prominent companies such as NVIDIA Corporation, Google Health/ DeepMind, Microsoft Healthcare (AI for Health), IBM Watson Health, Tempus Labs and Other Key Players.
The AI-driven precision medicine market is moderately fragmented, characterized by medium market consolidation. The ecosystem consists of Tier 1 players such as Roche (Flatiron Health, Foundation Medicine), Microsoft Healthcare, NVIDIA, and Siemens Healthineers with strong AI capabilities and global scale. Tier 2 players like Tempus Labs, IBM Watson Health, and Guardant Health are rapidly expanding influence, while Tier 3 innovators such as Paige AI, Freenome, and Caption Health are niche-focused. Buyer concentration is moderate, with increasing demand from research institutions and health systems, while supplier concentration is high, as AI model training relies heavily on limited, high-quality data sources and cloud infrastructure providers.

Recent Development and Strategic Overview:
- In April 2025, Tempus AI unveiled Tempus One, a portable artificial intelligence device, it provides treatment recommendations in real-time for the personalized management of cancers. The device cost-effectively enables doctors to rapidly select the best treatments without sophisticated systems through the informed understanding of genomics and clinical data. Built for daily clinics, this device is responding to the growing demand for rapid and affordable AI-based solutions. “Tempus One” has already been embraced by leading American hospitals and is generating traction as a straightforward yet meaningful solution for advancing precision oncology.
- In April 2025, PathAI has partnered with Mayo Clinic to roll out AI-enabled pathology models that provide real-time cancer diagnosis and staging capabilities from biopsy slides. The system enables pathologists to analyze tumor samples from a distance and with improved accuracy and consistency. The technology, which assists with a diagnosis right away, eliminates delays in diagnosis, especially among community hospitals evaluating samples, and encourages timely, personalized care plans. PathAI's AI precision care will soon be available to patients across the United States.
Report Scope
|
Attribute
|
Detail
|
|
Market Size in 2025
|
USD 0.7 Bn
|
|
Market Forecast Value in 2035
|
USD 9.7 Bn
|
|
Growth Rate (CAGR)
|
26.8%
|
|
Forecast Period
|
2025 – 2035
|
|
Historical Data Available for
|
2021 – 2024
|
|
Market Size Units
|
US$ Billion for Value
|
|
Report Format
|
Electronic (PDF) + Excel
|
|
Regions and Countries Covered
|
|
North America
|
Europe
|
Asia Pacific
|
Middle East
|
Africa
|
South America
|
- United States
- Canada
- Mexico
|
- Germany
- United Kingdom
- France
- Italy
- Spain
- Netherlands
- Nordic Countries
- Poland
- Russia & CIS
|
- China
- India
- Japan
- South Korea
- Australia and New Zealand
- Indonesia
- Malaysia
- Thailand
- Vietnam
|
- Turkey
- UAE
- Saudi Arabia
- Israel
|
- South Africa
- Egypt
- Nigeria
- Algeria
|
|
|
Companies Covered
|
|
|
- Foundation Medicine (Roche)
- Freenome
- Genalyte
- Google Health / DeepMind
|
|
- NVIDIA Corporation
- Oracle Health Sciences
- Owkin
|
- Paige AI
- PathAI
- Philips Healthcare
- Siemens Healthineers
|
- Tempus Labs
- Zebra Medical Vision
- Other key Players
|
AI-Driven Precision Medicine Market Segmentation and Highlights
|
Segment
|
Sub-segment
|
|
By Technology Type
|
- Machine Learning (ML)
- Deep Learning (DL)
- Natural Language Processing (NLP)
- Computer Vision
- Reinforcement Learning
- Big Data Analytics
- Others
|
|
By Component
|
- Software
- Predictive Modeling
- Decision Support
- Others
- Services
- Implementation
- Consulting
- Data Management
- Others
- Hardware
- AI chips
- Edge Devices
- Cloud Infrastructure
- Others
|
|
By Data Type
|
- Genomic Data
- Clinical Data (EHRs, medical imaging)
- Behavioral Data
- Environmental & Lifestyle Data
- Proteomic & Metabolomic Data
- Others
|
|
By Delivery Mode
|
- Cloud-based AI Solutions
- On-premise AI Systems
|
|
By Therapeutic Area
|
- Cancer
- Cardiovascular Diseases
- Neurological Disorders
- Infectious Diseases
- Others (Autoimmune, Endocrine Disorders)
|
|
By Application
|
- Oncology (Cancer Genomics, Tumor Profiling)
- Cardiology
- Neurology
- Immunology
- Pharmacogenomics
- Rare Diseases
- Infectious Diseases (e.g., COVID-19 AI applications)
- Others (Metabolic, Respiratory, etc.)
|
|
By End User
|
- Hospitals & Clinics
- Research & Academic Institutions
- Pharmaceutical & Biotechnology Companies
- Clinical Laboratories
- Government & Public Health Agencies
- Others
|
Frequently Asked Questions
The global AI-driven precision medicine market was valued at USD 0.7 Bn in 2025.
The global AI-driven precision medicine market industry is expected to grow at a CAGR of 26.8% from 2025 to 2035.
The rise in cases of tumors, rare genetic disorders and just the overall increase of chronic disease like diabetes and related heart disease along with other technological advancements in the domain of artificial intelligence are the prime drivers for the global AI-driven precision medicine market.
Machine learning with ~39% of the total market, contributed to the largest share of the AI-driven precision medicine market business in 2025.
North America is a more attractive region for vendors.
Berg Health, Butterfly Network, Caption Health, Flatiron Health (Roche), Foundation Medicine (Roche), Freenome, Genalyte, Google Health/ DeepMind, Guardant Health, IBM Watson Health, Microsoft Healthcare (AI for Health), NVIDIA Corporation, Oracle Health Sciences, Owkin, Paige AI, PathAI, Philips Healthcare, Siemens Healthineers, Tempus Labs, Zebra Medical Vision, Other key Players.
- 1. Research Methodology and Assumptions
- 1.1. Definitions
- 1.2. Research Design and Approach
- 1.3. Data Collection Methods
- 1.4. Base Estimates and Calculations
- 1.5. Forecasting Models
- 1.5.1. Key Forecast Factors & Impact Analysis
- 1.6. Secondary Research
- 1.6.1. Open Sources
- 1.6.2. Paid Databases
- 1.6.3. Associations
- 1.7. Primary Research
- 1.7.1. Primary Sources
- 1.7.2. Primary Interviews with Stakeholders across Ecosystem
- 2. Executive Summary
- 2.1. AI-Driven Precision Medicine Market Outlook
- 2.1.1. AI-Driven Precision Medicine Market Size (Value - US$ Billion), and Forecasts, 2021-2035
- 2.1.2. Compounded Annual Growth Rate Analysis
- 2.1.3. Growth Opportunity Analysis
- 2.1.4. Segmental Share Analysis
- 2.1.5. Geographical Share Analysis
- 2.2. Market Analysis and Facts
- 2.3. Supply-Demand Analysis
- 2.4. Competitive Benchmarking
- 2.5. Go-to- Market Strategy
- 2.5.1. Customer/ End-use Industry Assessment
- 2.5.2. Growth Opportunity Data, 2025-2035
- 2.5.2.1. Regional Data
- 2.5.2.2. Country Data
- 2.5.2.3. Segmental Data
- 2.5.3. Identification of Potential Market Spaces
- 2.5.4. GAP Analysis
- 2.5.5. Potential Attractive Price Points
- 2.5.6. Prevailing Market Risks & Challenges
- 2.5.7. Preferred Sales & Marketing Strategies
- 2.5.8. Key Recommendations and Analysis
- 2.5.9. A Way Forward
- 3. Industry Data and Premium Insights
- 3.1. Healthcare & Pharmaceutical Industry Overview, 2025
- 3.1.1. Healthcare & Pharmaceutical Industry Ecosystem Analysis
- 3.1.2. Key Trends for Healthcare & Pharmaceutical Industry
- 3.1.3. Regional Distribution for Healthcare & Pharmaceutical Industry
- 3.2. Supplier Customer Data
- 3.3. Source Roadmap and Developments
- 3.4. Trade Analysis
- 3.4.1. Import & Export Analysis, 2025
- 3.4.2. Top Importing Countries
- 3.4.3. Top Exporting Countries
- 3.5. Trump Tariff Impact Analysis
- 3.5.1. Manufacturer
- 3.5.2. Supply Chain
- 3.5.3. End Consumer
- 3.6. Raw Material Analysis
- 4. Market Overview
- 4.1. Market Dynamics
- 4.1.1. Drivers
- 4.1.1.1. Rising Incidence of Genetic Disorders with increasing Technological Advancements
- 4.1.2. Restraints
- 4.1.2.1. Expensive AI Models, Strict Regulatory Frameworks limiting the AI-Driven Precision Medicine Industry
- 4.2. Key Trend Analysis
- 4.3. Regulatory Framework
- 4.3.1. Key Regulations, Norms, and Subsidies, by Key Countries
- 4.3.2. Tariffs and Standards
- 4.3.3. Impact Analysis of Regulations on the Market
- 4.4. Value Chain Analysis
- 4.4.1. Component Suppliers
- 4.4.2. AI-Driven Precision Medicine Manufacturers
- 4.4.3. Dealers/Distributors
- 4.4.4. Wholesalers/ E-commerce Platform
- 4.4.5. End-users/ Customers
- 4.5. Cost Structure Analysis
- 4.5.1. Parameter’s Share for Cost Associated
- 4.5.2. COGP vs COGS
- 4.5.3. Profit Margin Analysis
- 4.6. Pricing Analysis
- 4.6.1. Regional Pricing Analysis
- 4.6.2. Segmental Pricing Trends
- 4.6.3. Factors Influencing Pricing
- 4.7. Porter’s Five Forces Analysis
- 4.8. PESTEL Analysis
- 4.9. AI-Driven Precision Medicine Market Demand
- 4.9.1. Historical Market Size – in Value (US$ Billion), 2021-2024
- 4.9.2. Current and Future Market Size – in Value (US$ Billion), 2025–2035
- 4.9.2.1. Y-o-Y Growth Trends
- 4.9.2.2. Absolute $ Opportunity Assessment
- 5. Competition Landscape
- 5.1. Competition structure
- 5.1.1. Fragmented v/s consolidated
- 5.2. Company Share Analysis, 2025
- 5.2.1. Global Company Market Share
- 5.2.2. By Region
- 5.2.2.1. North America
- 5.2.2.2. Europe
- 5.2.2.3. Asia Pacific
- 5.2.2.4. Middle East
- 5.2.2.5. Africa
- 5.2.2.6. South America
- 5.3. Product Comparison Matrix
- 5.3.1. Specifications
- 5.3.2. Market Positioning
- 5.3.3. Pricing
- 6. AI-Driven Precision Medicine Market Analysis, by Technology Type
- 6.1. Key Segment Analysis
- 6.2. AI-Driven Precision Medicine Market Size (Value - US$ Billion), Analysis, and Forecasts, by Technology Type, 2021-2035
- 6.2.1. Machine Learning (ML)
- 6.2.2. Deep Learning (DL)
- 6.2.3. Natural Language Processing (NLP)
- 6.2.4. Computer Vision
- 6.2.5. Reinforcement Learning
- 6.2.6. Big Data Analytics
- 6.2.7. Others
- 7. AI-Driven Precision Medicine Market Analysis, by Component
- 7.1. Key Segment Analysis
- 7.2. AI-Driven Precision Medicine Market Size (Value - US$ Billion), Analysis, and Forecasts, by Technology, 2021-2035
- 7.2.1. Software
- 7.2.1.1. Predictive Modeling
- 7.2.1.2. Decision Support
- 7.2.1.3. Others
- 7.2.2. Services
- 7.2.2.1. Implementation
- 7.2.2.2. Consulting
- 7.2.2.3. Data Management
- 7.2.2.4. Others
- 7.2.3. Hardware
- 7.2.3.1. AI chips
- 7.2.3.2. Edge Devices
- 7.2.3.3. Cloud Infrastructure
- 7.2.3.4. Others
- 8. AI-Driven Precision Medicine Market Analysis, by Data Type
- 8.1. Key Segment Analysis
- 8.2. AI-Driven Precision Medicine Market Size (Value - US$ Billion), Analysis, and Forecasts, by Technology, 2021-2035
- 8.2.1. Genomic Data
- 8.2.2. Clinical Data (EHRs, medical imaging)
- 8.2.3. Behavioral Data
- 8.2.4. Environmental & Lifestyle Data
- 8.2.5. Proteomic & Metabolomic Data
- 8.2.6. Others
- 9. AI-Driven Precision Medicine Market Analysis, by Delivery Mode
- 9.1. Key Segment Analysis
- 9.2. Omega-3 Market Size (Value - US$ Billion), Analysis, and Forecasts, by Distribution Channel, 2021-2035
- 9.2.1. Cloud-based AI Solutions
- 9.2.2. On-premise AI Systems
- 10. AI-Driven Precision Medicine Market Analysis, by Therapeutic Area
- 10.1. Key Segment Analysis
- 10.2. AI-Driven Precision Medicine Market Size (Volume-Million Units and Value - US$ Billion), Analysis, and Forecasts, by End-User, 2021-2035
- 10.2.1. Cancer
- 10.2.2. Cardiovascular Diseases
- 10.2.3. Neurological Disorders
- 10.2.4. Infectious Diseases
- 10.2.5. Others (Autoimmune, Endocrine Disorders)
- 11. AI-Driven Precision Medicine Market Analysis, by Application
- 11.1. Key Segment Analysis
- 11.2. AI-Driven Precision Medicine Market Size (Volume-Million Units and Value - US$ Billion), Analysis, and Forecasts, by End-User, 2021-2035
- 11.2.1. Oncology (Cancer Genomics, Tumor Profiling)
- 11.2.2. Cardiology
- 11.2.3. Neurology
- 11.2.4. Immunology
- 11.2.5. Pharmacogenomics
- 11.2.6. Rare Diseases
- 11.2.7. Infectious Diseases (e.g., COVID-19 AI applications)
- 11.2.8. Others (Metabolic, Respiratory, etc.)
- 12. AI-Driven Precision Medicine Market Analysis, by End-user
- 12.1. Key Segment Analysis
- 12.2. AI-Driven Precision Medicine Market Size (Volume-Million Units and Value - US$ Billion), Analysis, and Forecasts, by End-User, 2021-2035
- 12.2.1. Hospitals & Clinics
- 12.2.2. Research & Academic Institutions
- 12.2.3. Pharmaceutical & Biotechnology Companies
- 12.2.4. Clinical Laboratories
- 12.2.5. Government & Public Health Agencies
- 12.2.6. Others
- 13. AI-Driven Precision Medicine Market Analysis and Forecasts, by Region
- 13.1. Key Findings
- 13.2. AI-Driven Precision Medicine Market Size (Volume-Million Units and Value - US$ Billion), Analysis, and Forecasts, by Region, 2021-2035
- 13.2.1. North America
- 13.2.2. Europe
- 13.2.3. Asia Pacific
- 13.2.4. Middle East
- 13.2.5. Africa
- 13.2.6. South America
- North America AI-Driven Precision Medicine Market Analysis
- Key Segment Analysis
- Regional Snapshot
- North America AI-Driven Precision Medicine Market Size (Volume-Million Units and Value - US$ Billion), Analysis, and Forecasts, 2021-2035
- Technology Type
- Component
- Data Type
- Delivery Mode
- Therapeutic Area
- Application
- End-user
- Country
- USA AI-Driven Precision Medicine Market
- Country Segmental Analysis
- Technology Type
- Component
- Data Type
- Delivery Mode
- Therapeutic Area
- Application
- End-user
- Canada AI-Driven Precision Medicine Market
- Country Segmental Analysis
- Technology Type
- Component
- Data Type
- Delivery Mode
- Therapeutic Area
- Application
- End-user
- Mexico AI-Driven Precision Medicine Market
- Country Segmental Analysis
- Technology Type
- Component
- Data Type
- Delivery Mode
- Therapeutic Area
- Application
- End-user
- Europe AI-Driven Precision Medicine Market Analysis
- Key Segment Analysis
- Regional Snapshot
- Europe AI-Driven Precision Medicine Market Size (Volume-Million Units and Value - US$ Billion), Analysis, and Forecasts, 2021-2035
- Technology Type
- Component
- Data Type
- Delivery Mode
- Therapeutic Area
- Application
- End-user
- Country
- Germany
- United Kingdom
- France
- Italy
- Spain
- Netherlands
- Nordic Countries
- Poland
- Russia & CIS
- Rest of Europe
- Germany AI-Driven Precision Medicine Market
- Country Segmental Analysis
- Technology Type
- Component
- Data Type
- Delivery Mode
- Therapeutic Area
- Application
- End-user
- United Kingdom AI-Driven Precision Medicine Market
- Country Segmental Analysis
- Technology Type
- Component
- Data Type
- Delivery Mode
- Therapeutic Area
- Application
- End-user
- France AI-Driven Precision Medicine Market
- Country Segmental Analysis
- Technology Type
- Component
- Data Type
- Delivery Mode
- Therapeutic Area
- Application
- End-user
- Italy AI-Driven Precision Medicine Market
- Country Segmental Analysis
- Technology Type
- Component
- Data Type
- Delivery Mode
- Therapeutic Area
- Application
- Distribution Channel
- End-user
- Spain AI-Driven Precision Medicine Market
- Country Segmental Analysis
- Technology Type
- Component
- Data Type
- Delivery Mode
- Therapeutic Area
- Application
- End-user
- Netherlands AI-Driven Precision Medicine Market
- Country Segmental Analysis
- Technology Type
- Component
- Data Type
- Delivery Mode
- Therapeutic Area
- Application
- End-user
- Nordic Countries AI-Driven Precision Medicine Market
- Country Segmental Analysis
- Technology Type
- Component
- Data Type
- Delivery Mode
- Therapeutic Area
- Application
- End-user
- Poland AI-Driven Precision Medicine Market
- Country Segmental Analysis
- Technology Type
- Component
- Data Type
- Delivery Mode
- Therapeutic Area
- Application
- End-user
- Russia & CIS AI-Driven Precision Medicine Market
- Country Segmental Analysis
- Technology Type
- Component
- Data Type
- Delivery Mode
- Therapeutic Area
- Application
- End-user
- Rest of Europe AI-Driven Precision Medicine Market
- Country Segmental Analysis
- Technology Type
- Component
- Data Type
- Delivery Mode
- Therapeutic Area
- Application
- End-user
- Asia Pacific AI-Driven Precision Medicine Market Analysis
- Key Segment Analysis
- Regional Snapshot
- East Asia AI-Driven Precision Medicine Market Size (Volume-Million Units and Value - US$ Billion), Analysis, and Forecasts, 2021-2035
- Technology Type
- Component
- Data Type
- Delivery Mode
- Therapeutic Area
- Application
- End-user
- Country
- China
- India
- Japan
- South Korea
- Australia and New Zealand
- Indonesia
- Malaysia
- Thailand
- Vietnam
- Rest of Asia-Pacific
- China AI-Driven Precision Medicine Market
- Country Segmental Analysis
- Technology Type
- Component
- Data Type
- Delivery Mode
- Therapeutic Area
- Application
- End-user
- India AI-Driven Precision Medicine Market
- Country Segmental Analysis
- Technology Type
- Component
- Data Type
- Delivery Mode
- Therapeutic Area
- Application
- End-user
- Japan AI-Driven Precision Medicine Market
- Country Segmental Analysis
- Technology Type
- Component
- Data Type
- Delivery Mode
- Therapeutic Area
- Application
- End-user
- South Korea AI-Driven Precision Medicine Market
- Country Segmental Analysis
- Technology Type
- Component
- Data Type
- Delivery Mode
- Therapeutic Area
- Application
- End-user
- Australia and New Zealand AI-Driven Precision Medicine Market
- Country Segmental Analysis
- Technology Type
- Component
- Data Type
- Delivery Mode
- Therapeutic Area
- Application
- End-user
- Indonesia AI-Driven Precision Medicine Market
- Country Segmental Analysis
- Technology Type
- Component
- Data Type
- Delivery Mode
- Therapeutic Area
- Application
- End-user
- Malaysia AI-Driven Precision Medicine Market
- Country Segmental Analysis
- Technology Type
- Component
- Data Type
- Delivery Mode
- Therapeutic Area
- Application
- End-user
- Thailand AI-Driven Precision Medicine Market
- Country Segmental Analysis
- Technology Type
- Component
- Data Type
- Delivery Mode
- Therapeutic Area
- Application
- End-user
- Vietnam AI-Driven Precision Medicine Market
- Country Segmental Analysis
- Technology Type
- Component
- Data Type
- Delivery Mode
- Therapeutic Area
- Application
- End-user
- Rest of Asia Pacific AI-Driven Precision Medicine Market
- Country Segmental Analysis
- Technology Type
- Component
- Data Type
- Delivery Mode
- Therapeutic Area
- Application
- Distribution Channel
- End-user
- Middle East AI-Driven Precision Medicine Market Analysis
- Key Segment Analysis
- Regional Snapshot
- Middle East AI-Driven Precision Medicine Market Size (Volume-Million Units and Value - US$ Billion), Analysis, and Forecasts, 2021-2035
- Technology Type
- Component
- Data Type
- Delivery Mode
- Therapeutic Area
- Application
- End-user
- Country
- Turkey
- UAE
- Saudi Arabia
- Israel
- Rest of Middle East
- Turkey AI-Driven Precision Medicine Market
- Country Segmental Analysis
- Technology Type
- Component
- Data Type
- Delivery Mode
- Therapeutic Area
- Application
- End-user
- UAE AI-Driven Precision Medicine Market
- Country Segmental Analysis
- Technology Type
- Component
- Data Type
- Delivery Mode
- Therapeutic Area
- Application
- End-user
- Saudi Arabia AI-Driven Precision Medicine Market
- Country Segmental Analysis
- Technology Type
- Component
- Data Type
- Delivery Mode
- Therapeutic Area
- Application
- End-user
- Israel AI-Driven Precision Medicine Market
- Country Segmental Analysis
- Technology Type
- Component
- Data Type
- Delivery Mode
- Therapeutic Area
- Application
- End-user
- Rest of Middle East AI-Driven Precision Medicine Market
- Country Segmental Analysis
- Technology Type
- Component
- Data Type
- Delivery Mode
- Therapeutic Area
- Application
- End-user
- Africa AI-Driven Precision Medicine Market Analysis
- Key Segment Analysis
- Regional Snapshot
- Africa AI-Driven Precision Medicine Market Size (Volume-Million Units and Value - US$ Billion), Analysis, and Forecasts, 2021-2035
- Technology Type
- Component
- Data Type
- Delivery Mode
- Therapeutic Area
- Application
- End-user
- Country
- South Africa
- Egypt
- Nigeria
- Algeria
- Rest of Africa
- South Africa AI-Driven Precision Medicine Market
- Country Segmental Analysis
- Technology Type
- Component
- Data Type
- Delivery Mode
- Therapeutic Area
- Application
- End-user
- Egypt AI-Driven Precision Medicine Market
- Country Segmental Analysis
- Technology Type
- Component
- Data Type
- Delivery Mode
- Therapeutic Area
- Application
- End-user
- Nigeria AI-Driven Precision Medicine Market
- Country Segmental Analysis
- Technology Type
- Component
- Data Type
- Delivery Mode
- Therapeutic Area
- Application
- End-user
- Algeria AI-Driven Precision Medicine Market
- Country Segmental Analysis
- Technology Type
- Component
- Data Type
- Delivery Mode
- Therapeutic Area
- Application
- End-user
- Rest of Africa AI-Driven Precision Medicine Market
- Country Segmental Analysis
- Technology Type
- Component
- Data Type
- Delivery Mode
- Therapeutic Area
- Application
- End-user
- South America AI-Driven Precision Medicine Market Analysis
- Key Segment Analysis
- Regional Snapshot
- Central and South Africa AI-Driven Precision Medicine Market Size (Volume-Million Units and Value - US$ Billion), Analysis, and Forecasts, 2021-2035
- Device Type
- Technology Type
- Component
- Data Type
- Delivery Mode
- Therapeutic Area
- Application
- End-user
- Country
- Brazil
- Argentina
- Rest of South America
- Brazil AI-Driven Precision Medicine Market
- Country Segmental Analysis
- Technology Type
- Component
- Data Type
- Delivery Mode
- Therapeutic Area
- Application
- End-user
- Argentina AI-Driven Precision Medicine Market
- Country Segmental Analysis
- Technology Type
- Component
- Data Type
- Delivery Mode
- Therapeutic Area
- Application
- End-user
- Rest of South America AI-Driven Precision Medicine Market
- Country Segmental Analysis
- Technology Type
- Component
- Data Type
- Delivery Mode
- Therapeutic Area
- Application
- End-user
- Key Players/ Company Profile
- Berg Health
- Company Details/ Overview
- Company Financials
- Key Customers and Competitors
- Business/ Industry Portfolio
- Product Portfolio/ Specification Details
- Pricing Data
- Strategic Overview
- Recent Developments
- Butterfly Network
- Caption Health
- Flatiron Health (Roche)
- Foundation Medicine (Roche)
- Freenome
- Genalyte
- Google Health / DeepMind
- Guardant Health
- IBM Watson Health
- Microsoft Healthcare (AI for Health)
- NVIDIA Corporation
- Oracle Health Sciences
- Owkin
- Paige AI
- PathAI
- Philips Healthcare
- Siemens Healthineers
- Tempus Labs
- Zebra Medical Vision
- Other key Players
Note* - This is just tentative list of players. While providing the report, we will cover more number of players based on their revenue and share for each geography